Okada Takuro, Saotome Takashi, Nagao Toshitaka, Masubuchi Tatsuo, Fushimi Chihiro, Matsuki Takashi, Takahashi Hideaki, Miura Kouki, Tsukahara Kiyoaki, Tada Yuichiro
Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Department of Otolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
In Vivo. 2019 May-Jun;33(3):843-853. doi: 10.21873/invivo.11549.
BACKGROUND/AIM: The aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with locally advanced and/or recurrent/metastatic (LA/RM) salivary gland carcinoma (SGC).
This was a retrospective analysis of 24 patients that included six patients with AR-positive salivary duct carcinoma (SDC) after progressive disease treated with combined androgen blockade (CAB). Carboplatin (AUC5) and docetaxel (70 mg/m) were administered for six courses every three weeks.
The overall response rate was 42%, the median progression-free survival was 8.4 months, and the median overall survival was 26.4 months. Among the six patients with CAB-resistant SDC, two achieved a partial response and two long-term stable disease. Grade 3/4 neutropenia and anemia were observed in 20-30% of the patients; all adverse events were manageable.
Carboplatin/docetaxel combination therapy may be a chemotherapeutic option for patients with LA/RM SGC, and a valuable second-line chemotherapy for CAB-resistant, AR-positive SDC.
背景/目的：本研究旨在评估卡铂/多西他赛联合治疗局部晚期和/或复发/转移性（LA/RM）涎腺癌（SGC）患者的疗效和安全性。
这是一项对24例患者的回顾性分析，其中包括6例疾病进展后接受联合雄激素阻断（CAB）治疗的雄激素受体（AR）阳性涎腺导管癌（SDC）患者。每三周给予卡铂（AUC5）和多西他赛（70mg/m²），共六个疗程。
总缓解率为42%，中位无进展生存期为8.4个月，中位总生存期为26.4个月。在6例对CAB耐药的SDC患者中，2例获得部分缓解，2例病情长期稳定。20%-30%的患者出现3/4级中性粒细胞减少和贫血；所有不良事件均可控制。
卡铂/多西他赛联合治疗可能是LA/RM SGC患者的一种化疗选择，也是对CAB耐药、AR阳性SDC患者有价值的二线化疗方案。
